Immune checkpoint inhibitors for metastatic bladder cancer

Francesco Massari, Vincenzo Di Nunno, Marta Cubelli, Matteo Santoni, Michelangelo Fiorentino, Rodolfo Montironi, Liang Cheng, Anto Lopez-Beltran, Nicola Battelli, Andrea Ardizzoni

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Chemotherapy has represented the standard therapy for unresectable or metastatic urothelial carcinoma for more than 20 years. The growing knowledge of the interaction between tumour and immune system has led to the advent of new classes of drugs, the immune-checkpoints inhibitors, which are intended to change the current scenario. To date, immunotherapy is able to improve the overall responses and survival. Moreover, thanks to its safety profile immune-checkpoint inhibitors could be proposed also to patients unfit for standard chemotherapy. No doubts that these agents have started a revolution expected for years, but despite this encouraging results it appears clear that not all subjects respond to these agents and requiring the development of reliable predictive response factors able to isolate patients who can more benefit from these treatments as well as new strategies aimed to improve immunotherapy clinical outcome. In this review we describe the active or ongoing clinical trials involving Programmed Death Ligand 1 (PD-L1), Programmed Death receptor 1 (PD-1) and Cytotoxic-T Lymphocyte Antigen 4 (CTLA 4) inhibitors in urothelial carcinoma focusing our attention on the developing new immune-agents and combination strategies with immune-checkpoint inhibitors.

Original languageEnglish (US)
Pages (from-to)11-20
Number of pages10
JournalCancer Treatment Reviews
Volume64
DOIs
StatePublished - Mar 1 2018

Fingerprint

Urinary Bladder Neoplasms
Immunotherapy
CTLA-4 Antigen
Naphazoline
Carcinoma
Drug Therapy
Death Domain Receptors
Immune System
Clinical Trials
Ligands
Safety
Survival
Therapeutics
Pharmaceutical Preparations
Neoplasms

Keywords

  • Atezolizumab
  • Avelumab
  • Combination therapy
  • Durvalumab
  • Immune-checkpoint inhibitors
  • Ipilimumab
  • Nivolumab
  • Pembrolizumab
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Massari, F., Di Nunno, V., Cubelli, M., Santoni, M., Fiorentino, M., Montironi, R., ... Ardizzoni, A. (2018). Immune checkpoint inhibitors for metastatic bladder cancer. Cancer Treatment Reviews, 64, 11-20. https://doi.org/10.1016/j.ctrv.2017.12.007

Immune checkpoint inhibitors for metastatic bladder cancer. / Massari, Francesco; Di Nunno, Vincenzo; Cubelli, Marta; Santoni, Matteo; Fiorentino, Michelangelo; Montironi, Rodolfo; Cheng, Liang; Lopez-Beltran, Anto; Battelli, Nicola; Ardizzoni, Andrea.

In: Cancer Treatment Reviews, Vol. 64, 01.03.2018, p. 11-20.

Research output: Contribution to journalReview article

Massari, F, Di Nunno, V, Cubelli, M, Santoni, M, Fiorentino, M, Montironi, R, Cheng, L, Lopez-Beltran, A, Battelli, N & Ardizzoni, A 2018, 'Immune checkpoint inhibitors for metastatic bladder cancer', Cancer Treatment Reviews, vol. 64, pp. 11-20. https://doi.org/10.1016/j.ctrv.2017.12.007
Massari F, Di Nunno V, Cubelli M, Santoni M, Fiorentino M, Montironi R et al. Immune checkpoint inhibitors for metastatic bladder cancer. Cancer Treatment Reviews. 2018 Mar 1;64:11-20. https://doi.org/10.1016/j.ctrv.2017.12.007
Massari, Francesco ; Di Nunno, Vincenzo ; Cubelli, Marta ; Santoni, Matteo ; Fiorentino, Michelangelo ; Montironi, Rodolfo ; Cheng, Liang ; Lopez-Beltran, Anto ; Battelli, Nicola ; Ardizzoni, Andrea. / Immune checkpoint inhibitors for metastatic bladder cancer. In: Cancer Treatment Reviews. 2018 ; Vol. 64. pp. 11-20.
@article{0f5b7d357ada4ae2a83db919a8694973,
title = "Immune checkpoint inhibitors for metastatic bladder cancer",
abstract = "Chemotherapy has represented the standard therapy for unresectable or metastatic urothelial carcinoma for more than 20 years. The growing knowledge of the interaction between tumour and immune system has led to the advent of new classes of drugs, the immune-checkpoints inhibitors, which are intended to change the current scenario. To date, immunotherapy is able to improve the overall responses and survival. Moreover, thanks to its safety profile immune-checkpoint inhibitors could be proposed also to patients unfit for standard chemotherapy. No doubts that these agents have started a revolution expected for years, but despite this encouraging results it appears clear that not all subjects respond to these agents and requiring the development of reliable predictive response factors able to isolate patients who can more benefit from these treatments as well as new strategies aimed to improve immunotherapy clinical outcome. In this review we describe the active or ongoing clinical trials involving Programmed Death Ligand 1 (PD-L1), Programmed Death receptor 1 (PD-1) and Cytotoxic-T Lymphocyte Antigen 4 (CTLA 4) inhibitors in urothelial carcinoma focusing our attention on the developing new immune-agents and combination strategies with immune-checkpoint inhibitors.",
keywords = "Atezolizumab, Avelumab, Combination therapy, Durvalumab, Immune-checkpoint inhibitors, Ipilimumab, Nivolumab, Pembrolizumab, Urothelial carcinoma",
author = "Francesco Massari and {Di Nunno}, Vincenzo and Marta Cubelli and Matteo Santoni and Michelangelo Fiorentino and Rodolfo Montironi and Liang Cheng and Anto Lopez-Beltran and Nicola Battelli and Andrea Ardizzoni",
year = "2018",
month = "3",
day = "1",
doi = "10.1016/j.ctrv.2017.12.007",
language = "English (US)",
volume = "64",
pages = "11--20",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Immune checkpoint inhibitors for metastatic bladder cancer

AU - Massari, Francesco

AU - Di Nunno, Vincenzo

AU - Cubelli, Marta

AU - Santoni, Matteo

AU - Fiorentino, Michelangelo

AU - Montironi, Rodolfo

AU - Cheng, Liang

AU - Lopez-Beltran, Anto

AU - Battelli, Nicola

AU - Ardizzoni, Andrea

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Chemotherapy has represented the standard therapy for unresectable or metastatic urothelial carcinoma for more than 20 years. The growing knowledge of the interaction between tumour and immune system has led to the advent of new classes of drugs, the immune-checkpoints inhibitors, which are intended to change the current scenario. To date, immunotherapy is able to improve the overall responses and survival. Moreover, thanks to its safety profile immune-checkpoint inhibitors could be proposed also to patients unfit for standard chemotherapy. No doubts that these agents have started a revolution expected for years, but despite this encouraging results it appears clear that not all subjects respond to these agents and requiring the development of reliable predictive response factors able to isolate patients who can more benefit from these treatments as well as new strategies aimed to improve immunotherapy clinical outcome. In this review we describe the active or ongoing clinical trials involving Programmed Death Ligand 1 (PD-L1), Programmed Death receptor 1 (PD-1) and Cytotoxic-T Lymphocyte Antigen 4 (CTLA 4) inhibitors in urothelial carcinoma focusing our attention on the developing new immune-agents and combination strategies with immune-checkpoint inhibitors.

AB - Chemotherapy has represented the standard therapy for unresectable or metastatic urothelial carcinoma for more than 20 years. The growing knowledge of the interaction between tumour and immune system has led to the advent of new classes of drugs, the immune-checkpoints inhibitors, which are intended to change the current scenario. To date, immunotherapy is able to improve the overall responses and survival. Moreover, thanks to its safety profile immune-checkpoint inhibitors could be proposed also to patients unfit for standard chemotherapy. No doubts that these agents have started a revolution expected for years, but despite this encouraging results it appears clear that not all subjects respond to these agents and requiring the development of reliable predictive response factors able to isolate patients who can more benefit from these treatments as well as new strategies aimed to improve immunotherapy clinical outcome. In this review we describe the active or ongoing clinical trials involving Programmed Death Ligand 1 (PD-L1), Programmed Death receptor 1 (PD-1) and Cytotoxic-T Lymphocyte Antigen 4 (CTLA 4) inhibitors in urothelial carcinoma focusing our attention on the developing new immune-agents and combination strategies with immune-checkpoint inhibitors.

KW - Atezolizumab

KW - Avelumab

KW - Combination therapy

KW - Durvalumab

KW - Immune-checkpoint inhibitors

KW - Ipilimumab

KW - Nivolumab

KW - Pembrolizumab

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85041612415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041612415&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2017.12.007

DO - 10.1016/j.ctrv.2017.12.007

M3 - Review article

C2 - 29407369

AN - SCOPUS:85041612415

VL - 64

SP - 11

EP - 20

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

ER -